HUTCHMED (CHINA) LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 290 GBX | -4.61% |
|
+7.41% | +2.47% |
| Apr. 26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
| Apr. 26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
Presentation Operator MessageOperator (Operator)2022 Interim Results Conference Call and Webca...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
Sector
Pharmaceuticals
Calendar
2024-05-10
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.612
USD
Average target price
5.412
USD
Spread / Average Target
+49.84%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.47% | 3.08B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Transcript : HUTCHMED Limited, H1 2022 Earnings Call, Aug 01, 2022
